FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897892714> ?p ?o ?g. }

• W2897892714 endingPage "viii374" @default.
• W2897892714 startingPage "viii374" @default.
• W2897892714 abstract "Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A ligand, HLA-E, is upregulated in cancer, particularly SCCHN. Blocking NKG2A-HLA-E binding was shown to promote NK and T cell anti-tumor response. NK cell stimulation with a checkpoint inhibitor was also shown to enhance antibody dependent cellular cytotoxicity (ADCC) induced by cetuximab (Cetux). Currently, only Cetux and anti-PD1 antibodies are approved for SCCHN patients (pts) progressing after platinum-based therapy, with response rates ranging from 10-17%. Methods: This is a multicenter phase I/II trial. The phase I part was previously reported showing good safety profile of Mona/Cetux combination. In the phase II part presented here, pts received Mona (10 mg/kg q2weeks) and Cetux (loading 400 then 250 mg/m2 q1week). Patients were required to be progressing after platinum-based therapy and to have received < or = 2 prior lines of therapy. The primary endpoint was ORR per RECIST assessed every 8 weeks. Pts were treated until disease progression or unacceptable toxicity. Considering a P0 of 10%, P1 of 25%, α of 5% and power of 76%, the trial would be declared positive if > or = 8 out of the 40 enrolled patients showed a confirmed RECIST response. Results: All 40 planned pts have now been enrolled and as of March 9, 2018, 31 pts were evaluable for safety of which 26 were also evaluable for efficacy. These 31 pts received prior platinum, 45% prior anti-PD1 and 10% prior Cetux. The combination was well tolerated and 93% of adverse events (AE) were of Grade 1-2 severity with only 6 % treatment-related grade 3-4 AE. The most common AEs related to Mona were fatigue (17%), pyrexia (13%) and headache (10%). Eight out of 26 patients (31%) achieved a confirmed response (1 complete and 7 partial); 54% had SD. Remaining patients are not yet evaluable as they were enrolled recently. Updated ORR, duration of response, PFS and OS on all patients will be presented during the meeting. Conclusions: These data, if confirmed in subsequent trials, suggest that Mona/Cetux could emerge as a new treatment option for pts with heavily pretreated R/M SCCHN. Clinical trial identification: NCT02643550. Legal entity responsible for the study: Innate Pharma. Funding: Innate Pharma. Disclosure: J. Fayette: Membership on advisory board: BMS, Merck Serono, Innate Pharma. M.R. Posner: Data safety monitoring board: Merck, Cel Sci. C. Even, T. Seiwert: Advisory Board: Innate Pharma. D. Colevas: Consultant: Cota, Inc, KeyQuest Health; Research support: Bristol-Myers Squibb, IRX Therapeutics, Threshold Pharmaceuticals, AstraZeneca, Innate Pharma, PRA Health Sciences. F. Calmels, R. Zerbib, A. Boyer Chammard: Stock ownership and employment: Innate Pharma. R. Cohen: Grant to University of Pennsylvania: Innate Pharma. All other authors have declared no conflicts of interest." @default.
• W2897892714 created "2018-10-26" @default.
• W2897892714 creator A5002590653 @default.
• W2897892714 creator A5007050402 @default.
• W2897892714 creator A5008467612 @default.
• W2897892714 creator A5015582820 @default.
• W2897892714 creator A5017176613 @default.
• W2897892714 creator A5023777679 @default.
• W2897892714 creator A5024055928 @default.
• W2897892714 creator A5028065894 @default.
• W2897892714 creator A5045172802 @default.
• W2897892714 creator A5051498378 @default.
• W2897892714 creator A5070634393 @default.
• W2897892714 creator A5089578640 @default.
• W2897892714 creator A5090322942 @default.
• W2897892714 date "2018-10-01" @default.
• W2897892714 modified "2023-10-17" @default.
• W2897892714 title "Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)" @default.
• W2897892714 doi "https://doi.org/10.1093/annonc/mdy287.005" @default.
• W2897892714 hasPublicationYear "2018" @default.
• W2897892714 type Work @default.
• W2897892714 sameAs 2897892714 @default.
• W2897892714 citedByCount "13" @default.
• W2897892714 countsByYear W28978927142019 @default.
• W2897892714 countsByYear W28978927142020 @default.
• W2897892714 countsByYear W28978927142021 @default.
• W2897892714 countsByYear W28978927142022 @default.
• W2897892714 crossrefType "journal-article" @default.
• W2897892714 hasAuthorship W2897892714A5002590653 @default.
• W2897892714 hasAuthorship W2897892714A5007050402 @default.
• W2897892714 hasAuthorship W2897892714A5008467612 @default.
• W2897892714 hasAuthorship W2897892714A5015582820 @default.
• W2897892714 hasAuthorship W2897892714A5017176613 @default.
• W2897892714 hasAuthorship W2897892714A5023777679 @default.
• W2897892714 hasAuthorship W2897892714A5024055928 @default.
• W2897892714 hasAuthorship W2897892714A5028065894 @default.
• W2897892714 hasAuthorship W2897892714A5045172802 @default.
• W2897892714 hasAuthorship W2897892714A5051498378 @default.
• W2897892714 hasAuthorship W2897892714A5070634393 @default.
• W2897892714 hasAuthorship W2897892714A5089578640 @default.
• W2897892714 hasAuthorship W2897892714A5090322942 @default.
• W2897892714 hasBestOaLocation W28978927141 @default.
• W2897892714 hasConcept C121608353 @default.
• W2897892714 hasConcept C126322002 @default.
• W2897892714 hasConcept C143998085 @default.
• W2897892714 hasConcept C159654299 @default.
• W2897892714 hasConcept C203014093 @default.
• W2897892714 hasConcept C203092338 @default.
• W2897892714 hasConcept C2776530083 @default.
• W2897892714 hasConcept C2776833033 @default.
• W2897892714 hasConcept C2779984678 @default.
• W2897892714 hasConcept C2779998722 @default.
• W2897892714 hasConcept C29730261 @default.
• W2897892714 hasConcept C31760486 @default.
• W2897892714 hasConcept C40677261 @default.
• W2897892714 hasConcept C526805850 @default.
• W2897892714 hasConcept C535046627 @default.
• W2897892714 hasConcept C542903549 @default.
• W2897892714 hasConcept C71924100 @default.
• W2897892714 hasConceptScore W2897892714C121608353 @default.
• W2897892714 hasConceptScore W2897892714C126322002 @default.
• W2897892714 hasConceptScore W2897892714C143998085 @default.
• W2897892714 hasConceptScore W2897892714C159654299 @default.
• W2897892714 hasConceptScore W2897892714C203014093 @default.
• W2897892714 hasConceptScore W2897892714C203092338 @default.
• W2897892714 hasConceptScore W2897892714C2776530083 @default.
• W2897892714 hasConceptScore W2897892714C2776833033 @default.
• W2897892714 hasConceptScore W2897892714C2779984678 @default.
• W2897892714 hasConceptScore W2897892714C2779998722 @default.
• W2897892714 hasConceptScore W2897892714C29730261 @default.
• W2897892714 hasConceptScore W2897892714C31760486 @default.
• W2897892714 hasConceptScore W2897892714C40677261 @default.
• W2897892714 hasConceptScore W2897892714C526805850 @default.
• W2897892714 hasConceptScore W2897892714C535046627 @default.
• W2897892714 hasConceptScore W2897892714C542903549 @default.
• W2897892714 hasConceptScore W2897892714C71924100 @default.
• W2897892714 hasLocation W28978927141 @default.
• W2897892714 hasOpenAccess W2897892714 @default.
• W2897892714 hasPrimaryLocation W28978927141 @default.
• W2897892714 hasRelatedWork W1956415942 @default.
• W2897892714 hasRelatedWork W1996158748 @default.
• W2897892714 hasRelatedWork W2047962734 @default.
• W2897892714 hasRelatedWork W2062707457 @default.
• W2897892714 hasRelatedWork W2081836551 @default.
• W2897892714 hasRelatedWork W2126488520 @default.
• W2897892714 hasRelatedWork W2423163941 @default.
• W2897892714 hasRelatedWork W2792959778 @default.
• W2897892714 hasRelatedWork W3012537123 @default.
• W2897892714 hasRelatedWork W3154194420 @default.
• W2897892714 hasVolume "29" @default.
• W2897892714 isParatext "false" @default.
• W2897892714 isRetracted "false" @default.
• W2897892714 magId "2897892714" @default.
• W2897892714 workType "article" @default.